Peptide receptor radionuclide therapy for advanced neuroendocrine tumors

Abstract

Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a suitable β-emitting radionuclide, able to irradiate tumors and their metastases via internalization through a specific receptor (usually somatostatin S2), over-expressed on the cell membrane. After almost 2 decades of experience, PRRT, with either (90)Y-octreotide or (177)Lu-octreotate, has established itself to be an efficient and effective therapeutic modality. As a treatment, it is relatively safe up to the known thresholds of absorbed and bio-effective isotope dosages and the renal and hematological toxicity profiles are acceptable if adequate protective measures are undertaken.

Keywords: Bone marrow; Bronchopulmonary; Carcinoid; Gastroenteropancreatic neuroendocrine tumor; Hepatic neuroendocrine metastasis; PRRT; Peptide receptor radionuclide therapy; Renal toxicity.